Our Science: A Breakthogh In Fighting Cancer
At Mitomed, our R&D teams have bold goals and solutions that no one else has attempted. And we want to be there first. First in class with a novel approach to treating cancer.
Our Research and Development Approach
Science and innovation are the lifeblood of our company. We’re pursuing new ways to address one of the world’s greatest challenges – to cure cancer.
MitoMed’s founders demonstrated that NAF-1 is essential for cancer cell survival. Their studies suggest that NAF-1 is a major player in the metabolic pathways of cancer cells through its effects on cellular distribution of iron ions, mitochondrial ROS formation, stabilization of HIF1α and induction of apoptosis. Alterations in NAF-1 expression therefore affect major gene networks and metabolic pathways involved in the survival and proliferation of cancer cells. Mitomed’s drugs are engineered to specifically enter cancer cells due to their different membrane structure and to disrupt the activity of NAF-1. This leads to an inability to handle the ROS they generate, killing the cancer cells.
MM101 is a first-in-class dual-targeting drug that selectively kills cancer cells due to differential membrane characteristics and increased metabolic stress compared to normal cells. Preliminary data suggests that MM101 may have broad spectrum therapeutic activity in many different types of cancer.
Mitomed © Copyright. All rights reserved.
We need your consent to load the translations
We use a third-party service to translate the website content that may collect data about your activity. Please review the details in the privacy policy and accept the service to view the translations.